{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:50:41Z","timestamp":1791561041547,"version":"4.3.4"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JGO"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Burkitt\u2019s lymphoma (BL) is a common HIV-associated lymphoma in South Africa. B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt\u2019s lymphoma (BL\/DLBCL) also occurs in HIV infection. Outcomes of HIV-infected patients with BL or BL\/DLBCL in a resource-constrained setting are not defined. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> We performed a retrospective study of HIV-positive patients with BL or BL\/DLBCL treated from 2004 to 2012 with curative intent at a publically funded academic medical center in South Africa. Differences between BL and BL\/DLBCL, survival outcomes, and factors associated with survival were analyzed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> There were 35 patients with either HIV-associated BL (24) or BL\/DLBCL (11) who met study criteria. Median CD4<jats:sup>+<\/jats:sup> T-lymphocyte count at lymphoma diagnosis was 188 cells\/\u03bcL (range, 10 to 535 cells\/\u03bcL). Patients with BL\/DLBCL were significantly older and had less bone marrow involvement and lower baseline serum lactase dehydrogenase than patients with BL. Eighty-nine percent of patients presented with advanced disease, and 25% had baseline CNS involvement. Chemotherapy regimens consisted of cytoreduction with low-dose cyclophosphamide, vincristine, and prednisone followed by induction with vincristine, methotrexate, cyclophosphamide, doxorubicin and prednisone (LMB 86; 57%); hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine (hyper-CVAD; 20%); cyclophosphamide, doxorubicin, vincristine, and prednisone and high-dose methotrexate with leucovorin rescue on day 10 with accompanying prophylactic IT chemotherapy (Stanford regimen; 14%); and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-like; 9%) regimens. Twenty-three patients received CNS treatment or prophylaxis, and 31 received concurrent combination antiretroviral therapy. Two-year overall survival was 38% (95% CI, 22% to 54%) and 2-year event-free survival was 23% (95% CI, 11% to 38%), with no difference between histologic subtypes. Common causes of death were infection (41%) and CNS disease progression or systemic relapse (41%). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Cure of HIV-associated BL and BL\/DLBCL with intensive regimens is possible in resource-limited settings, but lower toxicity regimens, improved CNS prophylaxis, and increased resources for supportive care are required. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jgo.2015.002378","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T03:23:27Z","timestamp":1472700207000},"page":"218-226","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":9,"title":["Burkitt\u2019s Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt\u2019s Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital"],"prefix":"10.1200","volume":"3","author":[{"given":"Gerhard","family":"Sissolak","sequence":"first","affiliation":[{"name":"Gerhard Sissolak, Tonya M. Esterhuizen, Nooroudien Mohamed, and Danie Kotze, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa; Matthew Seftel, University of Manitoba, Winnipeg, Manitoba, Canada; and Thomas S. Uldrick, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[{"name":"Gerhard Sissolak, Tonya M. Esterhuizen, Nooroudien Mohamed, and Danie Kotze, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa; Matthew Seftel, University of Manitoba, Winnipeg, Manitoba, Canada; and Thomas S. Uldrick, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[{"name":"Gerhard Sissolak, Tonya M. Esterhuizen, Nooroudien Mohamed, and Danie Kotze, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa; Matthew Seftel, University of Manitoba, Winnipeg, Manitoba, Canada; and Thomas S. Uldrick, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya M.","family":"Esterhuizen","sequence":"additional","affiliation":[{"name":"Gerhard Sissolak, Tonya M. Esterhuizen, Nooroudien Mohamed, and Danie Kotze, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa; Matthew Seftel, University of Manitoba, Winnipeg, Manitoba, Canada; and Thomas S. Uldrick, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nooroudien","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Gerhard Sissolak, Tonya M. Esterhuizen, Nooroudien Mohamed, and Danie Kotze, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa; Matthew Seftel, University of Manitoba, Winnipeg, Manitoba, Canada; and Thomas S. Uldrick, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danie","family":"Kotze","sequence":"additional","affiliation":[{"name":"Gerhard Sissolak, Tonya M. Esterhuizen, Nooroudien Mohamed, and Danie Kotze, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa; Matthew Seftel, University of Manitoba, Winnipeg, Manitoba, Canada; and Thomas S. Uldrick, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3788"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20254"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09236.x"},{"key":"B5","first-page":"1508","volume":"22","author":"Aldoss IT","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0405"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2011.01.007"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181bf5544"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<766::AID-CNCR21>3.0.CO;2-V"},{"key":"B10","first-page":"445","volume":"88","author":"Oriol A","year":"2003","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2007.0124"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051771"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23522"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182a03e9b"},{"key":"B17","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.6.368"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn191"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2008.0174"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10365"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v13i3.125"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623900"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600685467"},{"key":"B26","doi-asserted-by":"crossref","unstructured":"de Leval L, Hasserjian RP: Diffuse large B-cell lymphomas and Burkitt lymphoma. Hematol Oncol Clin North Am 23:791-827, 2009","DOI":"10.1016\/j.hoc.2009.04.004"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv036"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1982"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802311458"}],"container-title":["Journal of Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JGO.2015.002378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:11:25Z","timestamp":1653808285000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JGO.2015.002378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1200\/JGO.2015.002378"],"URL":"https:\/\/doi.org\/10.1200\/jgo.2015.002378","relation":{},"ISSN":["2378-9506"],"issn-type":[{"value":"2378-9506","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"2016-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}